Today: 9 June 2026
Snowflake Shares Rise Ahead of Results With AI Demand in Focus
20 May 2026
2 mins read

Snowflake Shares Rise Ahead of Results With AI Demand in Focus

New York, May 20, 2026, 04:12 EDT

Snowflake gained on Tuesday, moving 3.2% higher to $169.55 in recent trade, after BofA Securities bumped up its price target on the data-cloud name. The firm expects solid fiscal first-quarter numbers next week, giving some lift to a software stock that’s been lagging this year, market data show.

Snowflake is set to report results after the U.S. market closes on May 27, covering the quarter to April 30. The release will show if corporate budgets for data and AI tools are still turning into product revenue, which is the main sales metric watched for Snowflake’s platform.

Snowflake set a tough target for investors. On its last earnings, the company guided to first-quarter fiscal 2027 product revenue between $1.262 billion and $1.267 billion, a 27% gain. Full-year product revenue is estimated at $5.66 billion, also up 27%.

BofA bumped its price target on Snowflake up to $205 from $195 and stuck with its Buy call, according to Investing.com. Analyst Koji Ikeda said demand at Snowflake still looks solid. Ikeda said this quarter shouldn’t change BofA’s view that the company is taking share in the AI business-intelligence space.

BofA expects the “robust demand” for Snowflake to keep going through the year, Sherwood reported. The note called Snowflake a “share gainer” in AI business intelligence, which the firm sees as a market where companies tap data and software for quicker decisions. Sherwood News

Mizuho Securities also weighed in. The firm said channel checks for Snowflake, Palo Alto Networks and CrowdStrike looked positive before earnings, based on calls with customers, partners and resellers.

Snowflake is still seeing demand for data modernization and growing interest in its AI offerings, StockStory said on TradingView. Newer tools like Snowflake Intelligence, which is used to query enterprise data, and Cortex Code, which targets developers working on code, are part of that trend.

Software shares have had a tough run lately. StockStory called out concerns about a possible “SaaS Rout of 2026” putting pressure on the group, with some investors worried artificial intelligence could disrupt the software-as-a-service business model—subscription-based software companies sell online. TradingView

Snowflake gave bulls some fuel after its last quarter. CEO Sridhar Ramaswamy told Reuters the company landed its biggest deal so far, saying it’s “over $400 million.” The report also said Snowflake’s fiscal 2027 product revenue forecast beat the average LSEG analyst estimate. Snowflake, which competes with Databricks, has signed multiyear $200 million agreements with OpenAI and Anthropic to use their models in its platform. Reuters

The setup still looks messy. BofA flagged some short-term demand headwinds out of the Middle East, though it said revenue there was small. At the same time, Investing.com said UBS and Evercore ISI cut their price targets, pointing to AI competition and a slowdown in Snowflake’s main cloud data-warehousing business.

Next week’s earnings will be under the microscope. Snowflake needs to prove customers keep storing and analyzing more data on its platform. The company also has to show its AI efforts are driving real growth, not just adding hype to the software sector.

Stock Market Today

  • Soybean Prices Decline Amid Lower Export Shipments and Reduced Speculative Positions
    June 9, 2026, 9:21 AM EDT. Soybean prices fell between 2 and 5 ½ cents on Monday, with the national average cash price dropping to $10.58 3/4 per bushel. Export shipments for the week ending June 4 decreased by 21.2% from the previous week, totaling 398,186 MT, and are down 28.8% year-over-year. Key buyers included Egypt, China, and Mexico. Marketing year exports stand 20.3% lower compared to last year. Meanwhile, speculative traders reduced their net long positions in soybean futures and options by 33,502 contracts, signaling cautious market sentiment. Soymeal and soy oil futures also declined modestly. A private export sale of 264,000 MT was reported for the 2026/27 season, but overall market pressure weighs on prices going into the week.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus
Previous Story

SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

Astera Labs Stock Surges: The AI Networking Bet Traders Are Chasing Before Nvidia Results
Next Story

Astera Labs Stock Surges: The AI Networking Bet Traders Are Chasing Before Nvidia Results

Go toTop